AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Healthcare Stocks Under the Spotlight: Sarepta Therapeutics, Zimmer Biomet Holdings, and Eli Lilly & Co.
ByAinvest
Tuesday, Jul 15, 2025 8:05 pm ET1min read
Analysts have mixed opinions on healthcare stocks Sarepta Therapeutics, Zimmer Biomet Holdings, and Eli Lilly & Co. Barclays analyst Gena Wang maintained a Buy rating on Sarepta Therapeutics with a $29.00 price target, while analyst Matt Miksic maintained a Sell rating on Zimmer Biomet Holdings with a $112.00 price target. Eli Lilly & Co received no analyst updates.
Analysts have presented mixed opinions on healthcare stocks Sarepta Therapeutics, Zimmer Biomet Holdings, and Eli Lilly & Co. [1]Barclays analyst Gena Wang maintained a Buy rating on Sarepta Therapeutics with a $29.00 price target. Wang cited the company's promising pipeline and potential for growth as reasons for the positive outlook. However, Sarepta Therapeutics faces a class action lawsuit for alleged securities law violations, which could impact its stock performance [2].
In contrast, analyst Matt Miksic maintained a Sell rating on Zimmer Biomet Holdings with a $112.00 price target. Miksic's concerns include the company's recent acquisition of Monogram Technologies, which may not provide immediate revenue benefits and could strain financial resources. Additionally, Zimmer Biomet faces a patent infringement lawsuit from Treace Medical Concepts [3].
Eli Lilly & Co received no analyst updates, but the stock closed at $771.75 on July 1, 2025, down 3.45% from the previous trading session. The stock underperformed the S&P 500, which registered a daily loss of 0.4%, and the Dow, which lost 0.98% [4].
References:
[1] https://www.morningstar.com/news/pr-newswire/20250714la29229/srpt-shareholders-have-the-right-to-lead-the-sarepta-therapeutics-inc-securities-lawsuit-contact-the-djs-law-group-before-the-final-deadline-srpt
[2] https://www.marketbeat.com/stocks/NYSE/ZBH/
[3] https://www.investing.com/news/analyst-ratings/citi-maintains-neutral-rating-on-zimmer-biomet-stock-amid-monogram-acquisition-93CH-4134119
[4] https://finance.yahoo.com/news/eli-lilly-lly-dips-more-214503427.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet